Tom Powles/bartscancer.london
May 26, 2025, 08:40
Tom Powles: Bladder Cancer Abstract Session at ASCO 2025
Tom Powles, Professor at the University of London, shared a post on X:
“Bladder cancer ASCO 2025
1) Ipi/nivo vs 1st line chemo (HR 0.79)-near miss
2) maintenance SG/PD-L1 vs PD-L1 (PFS HR0.49)-still relevant?
3) CIS subset analysis for salanlimab in NMIBC-patent selection for therapy?
4) A new Nectin4 ADC 9MW/PD1 in phase II RR=88%!
5) EVP update on RR/tox.”
More posts featuring ASCO 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 26, 2025, 13:46
May 26, 2025, 13:08
May 26, 2025, 12:58
May 26, 2025, 11:25